Anti-serum with anti-autoantibody activity decreases autoantibody-positive B lymphocytes and type 1 diabetes of female NOD mice

References

• Eisenbarth, G. S. 1986. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 314: 1360–1368
   PubMed Web of Science ®Google Scholar
• Wilmot-Roussel, H., D. J. Levy, C. Carette, et al. 2013. Factors associated with the presence of glutamic acid decarboxylase and islet antigen-2 autoantibodies in patients with long-standing type 1 diabetes. Diabetes Metab. 39: 244–249
   PubMed Web of Science ®Google Scholar
• Massa, O., M. Alessio, L. Russo, et al. 2013. Serological Proteome Analysis (SERPA) as a tool for the identification of new candidate autoantigens in type 1 diabetes. J. Proteomics. 82: 263–273
   PubMed Web of Science ®Google Scholar
• Palmer, J. P., C. M. Asplin, P. Clemons, et al. 1983. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 222: 1337–1339
   PubMed Web of Science ®Google Scholar
• Kaufman, D. L., M. G. Erlander, M. Clare-Salzler, et al. 1992. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J. Clin. Invest. 89: 283–292
   PubMed Web of Science ®Google Scholar
• Lu, J., Q. Li, H. Xie, et al. 1996. Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc. Natl. Acad. Sci. USA. 93: 2307–2311
   PubMed Web of Science ®Google Scholar
• Ma, W., A. Ribeiro-Da-Silva, Y. De Koninck, et al. 1996. Quantitative analysis of substance P-immunoreactive boutons on physiologically characterized dorsal horn neurons in the cat lumbar spinal cord. J. Comp. Neurol. 376: 45–64
   PubMed Web of Science ®Google Scholar
• Yu, L., Y. Liu, D. Miao, et al. 2010. Triple chimeric islet autoantigen IA2-ZnT8WR to facilitate islet autoantibody determination. J. Immunol. Methods. 353: 20–23
   PubMed Web of Science ®Google Scholar
• Skarstrand, H., A. Lernmark, F. Vaziri-Sani. 2013. Antigenicity and epitope specificity of ZnT8 autoantibodies in type 1 diabetes. Scand. J. Immunol. 77: 21–29
   PubMed Web of Science ®Google Scholar
• Enee, E., R. Kratzer, J. B. Arnoux, et al. 2012. ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. Diabetes. 61: 1779–1784
   PubMed Web of Science ®Google Scholar
• Andersen, M. K., T. Harkonen, C. Forsblom, et al. 2013. Zinc transporter type 8 autoantibodies (ZnT8A): prevalence and phenotypic associations in latent autoimmune diabetes patients and patients with adult onset type 1 diabetes. Autoimmunity 46: 251–258
   PubMed Web of Science ®Google Scholar
• Vaziri-Sani, F., S. Oak, J. Radtke, et al. 2010. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity 43: 598–606
   PubMed Web of Science ®Google Scholar
• Trabucchi, A., N. I. Faccinetti, L. L. Guerra, et al. 2012. Detection and characterization of ZnT8 autoantibodies could help to screen latent autoimmune diabetes in adult-onset patients with type 2 phenotype. Autoimmunity 45: 137–142
   PubMed Web of Science ®Google Scholar
• Maclaren, N., M. Lan, R. Coutant, et al. 1999. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (Type 1) diabetes in relatives. J. Autoimmun. 12: 279–287
   PubMed Web of Science ®Google Scholar
• Taplin, C. E., and J. M. Barker. 2008. Autoantibodies in type 1 diabetes. Autoimmunity. 41: 11–18
   PubMed Web of Science ®Google Scholar
• Wan, E. C., T. P. Gordon, and M. W. Jackson. 2008. Autoantibodies to calcium channels in type 1 diabetes mediate autonomic dysfunction by different mechanisms in colon and bladder and are neutralized by antiidiotypic antibodies. J. Autoimmun. 31: 66–72
   PubMed Web of Science ®Google Scholar
• Inoue, Y., T. Kaifu, A. Sugahara-Tobinai, et al. 2007. Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice. J. Immunol. 179: 764–774
   PubMed Web of Science ®Google Scholar
• Primo, M. E., H. Niepomniszcze, E. Poskus, et al. 2008. Frequency of pancreatic beta-cell autoimmunity markers in patients with autoimmune thyroid disease. Medicina (B Aires). 68: 37–42
   PubMed Web of Science ®Google Scholar
• Greeley, S. A., M. Katsumata, L. Yu, et al. 2002. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat. Med. 8: 399–402
   PubMed Web of Science ®Google Scholar
• Marino, E., P. A. Silveira, J. Stolp, and S. T. Grey. 2011. B cell-directed therapies in type 1 diabetes. Trends Immunol. 32: 287–294
   PubMed Web of Science ®Google Scholar
• Hampe, C. S. 2012. Protective role of anti-idiotypic antibodies in autoimmunity - lessons for type 1 diabetes. Autoimmunity. 45: 320–331
   PubMed Web of Science ®Google Scholar
• Arnson, Y., Y. Shoenfeld, and H. Amital. 2009. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity. 42: 553–560
   PubMed Web of Science ®Google Scholar
• Corte-Real, J., N. Duarte, L. Tavares, and C. Penha-Goncalves. 2009. Autoimmunity triggers in the NOD mouse: a role for natural auto-antibody reactivities in type 1 diabetes. Ann. N. Y. Acad. Sci. 1173: 442–448
   PubMed Web of Science ®Google Scholar
• Bonifacio, E., M. Atkinson, G. Eisenbarth, et al. 2001. International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. Diabetes. 50: 2451–2458
   PubMed Web of Science ®Google Scholar
• Hu, Y. X., J. Y. Guo, L. Shen, et al. 2002. Get effective polyclonal antisera in one month. Cell. Res. 12: 157–160
   PubMed Web of Science ®Google Scholar
• T-Barros S. V., T. A-Beherens, A. R-Cardozo, et al. 2003. Spastic tetraparesis as a sequela of bacterial meningitis. Rev. Neurol. 37: 722–725
   PubMed Web of Science ®Google Scholar
• Bluestone, J. A., K. Herold, and G. Eisenbarth. 2010. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 464: 1293–1300
   PubMed Web of Science ®Google Scholar
• Sreenan, S., A. J. Pick, M. Levisetti, et al. 1999. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Diabetes. 48: 989–996
   PubMed Web of Science ®Google Scholar
• Culina, S., C. Boitard, and R. Mallone. 2011. Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks? Clin. Dev. Immunol. 2011: 286248--286262
   Google Scholar
• Brorsson, C., F. Vaziri-Sani, R. Bergholdt, et al.; Danish Study Group of Childhood Diabetes. 2011. Correlations between islet autoantibody specificity and the SLC30A8 genotype with HLA-DQB1 and metabolic control in new onset type 1 diabetes. Autoimmunity. 44: 107–114
   PubMed Web of Science ®Google Scholar
• Thomas, J. W., P. L. Kendall, and H. G. Mitchell. 2002. The natural autoantibody repertoire of nonobese diabetic mice is highly active. J. Immunol. 169: 6617–6624
   PubMed Web of Science ®Google Scholar
• Bingley, P. J., E. Bonifacio, A. J. Williams, et al. 1997. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes. 46: 1701–1710
   PubMed Web of Science ®Google Scholar
• Miller, S. A., and E. St Onge. 2011. Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus. Expert. Opin. Biol. Ther. 11: 1525–1532
   PubMed Web of Science ®Google Scholar
• Hu, C., H. Ding, X. Zhang, et al. 2013. Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes. Diabetes. 60: 2914–2921
   Google Scholar
• Serreze, D. V., H. D. Chapman, M. Niens, et al. 2011. Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes. 60: 2914–2921
   PubMed Web of Science ®Google Scholar
• McInerney, M. F., S. B. Pek, and D. W. Thomas. 1991. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes. 40: 715–725
   PubMed Web of Science ®Google Scholar
• Yagi, H., M. Matsumoto, Y. Kishimoto, et al. 1991. Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD mouse. II. Suppression of pathogenesis by macrophage transfer from BCG-vaccinated mice. Cell. Immunol. 138: 142–149
   PubMed Web of Science ®Google Scholar
• Denes, B., I. Fodor, and W. H. Langridge. 2013. Persistent suppression of type 1 diabetes by a multicomponent vaccine containing a cholera toxin B subunit-autoantigen fusion protein and complete Freund's adjuvant. Clin. Dev. Immunol. 2013: 578786--578801
   PubMedGoogle Scholar